English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Received: 10 October 2019 Accepted: 5 January 2020 The patent system is a double-edged sword: for the pharmaceutical industry, the system stimulates the innovation of R&D subjects, and effectively protects the drugs; for the public, the system facilitates the monopoly of pharmaceutical giants, pushing up the prices of patented drugs. Hence, the patent system results in the conflict between accessibility and patent protection of drugs. This paper explains the necessity of the patent system, identifies the problem of excessively high drug prices induced by patent monopoly, and proposes to regulate drug prices by levying the excess profits tax (EPT). Moreover, the master-slave game model was introduced to quantify the decision-making behaviors of the government and the pharmaceutical enterprise. The results show that the patent system can stimulate innovation in the pharmaceutical industry; as an auxiliary means, a reasonable EPT helps to regulate the prices of patented drugs; a suitable tax burden makes up for the lack of market regulation, and corrects the public losses induced by the monopoly of patent rights, thereby mitigating the conflict between accessibility and patent protection of drugs and enhancing the overall social welfare. The research findings shed new light on government regulation of the pharmaceutical industry.

Solving the Conflict Between Accessibility and Patent Protection of Drugs Based on Public Safety